Rheumatology and Clinical Immunology, Spedali Civili, University of Brescia, Brescia, Italy.
J Autoimmun. 2012 May;38(2-3):J197-208. doi: 10.1016/j.jaut.2011.11.010. Epub 2011 Dec 26.
Multidisciplinary approach and patient counselling have been the key points in the improvement of the management of pregnancy in women with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). Most of these women can have successful pregnancy when thoroughly informed and instructed on several different issues. Disease activity should be in stable remission prior to pregnancy in order to reduce the chance for flare during pregnancy. To this purpose, medications must be modulated: "safe" drugs should be continued throughout pregnancy, embryotoxic/foetotoxic drugs should be withdrawn timely, and beneficial drugs such as low dose aspirin and heparin should be added for prophylaxis of maternal and foetal outcome, especially in the presence of antiphospholipid antibodies. The safety profile of anti-rheumatic drugs during pregnancy and breastfeeding should be kept constantly updated, as new data from inadvertent exposure accumulates and new drugs (especially biological agents) are available. Patients may carry autoantibodies that can negatively affect the baby, being neonatal lupus the prototypical case of passively acquired autoimmunity. Research has been greatly active in this field and more information on risk stratification and management are now available for counselling. The effect of both autoantibodies and drug exposure has been evaluated in the offspring: some concerns about learning disabilities have been raised, but these are treatable conditions that are likely to be overcome. To counsel a woman with SLE/APS during childbearing age means also to deal with contraception. Despite the "preferred choice" - combined oral contraceptive - may not be suitable for most of the patients, other options are available and should be offered and discussed with the patient. Fertility is not generally affected in SLE/APS patients, but those cases who require assisted reproduction techniques should be carefully evaluated and managed.
多学科方法和患者咨询一直是改善系统性红斑狼疮 (SLE) 和抗磷脂综合征 (APS) 女性妊娠管理的关键。当这些女性在许多不同问题上得到充分告知和指导时,大多数都可以成功妊娠。为了降低妊娠期间疾病活动的风险,应在妊娠前使疾病处于稳定缓解状态。为此,必须调节药物:“安全”药物应在整个妊娠期间持续使用,胚胎毒性/胎儿毒性药物应及时停用,应添加低剂量阿司匹林和肝素等有益药物,以预防母婴结局,尤其是在存在抗磷脂抗体的情况下。随着意外暴露的新数据不断积累,以及新药物(尤其是生物制剂)的出现,应不断更新妊娠和哺乳期抗风湿药物的安全性概况。患者可能携带自身抗体,这些自身抗体可能会对婴儿产生负面影响,新生儿狼疮是被动获得自身免疫的典型病例。该领域的研究非常活跃,现在有更多关于风险分层和管理的信息可供咨询。自身抗体和药物暴露对后代的影响已经得到了评估:有人对学习障碍提出了一些担忧,但这些都是可治疗的情况,很可能会得到克服。为生育年龄的 SLE/APS 女性提供咨询,还意味着要处理避孕问题。尽管联合口服避孕药是“首选”,但它可能不适合大多数患者,还有其他选择,应向患者提供并与患者讨论。SLE/APS 患者的生育能力通常不受影响,但那些需要辅助生殖技术的患者应仔细评估和管理。